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Liver resection for metastatic colorectal cancer 
Shunzaburo Iwatsuki, M.D., Carlos O. Esquivel, M.D., Ph.D., Robert D. Gordon, M.D., 
and Thomas E. Starzl, M.D., Ph.D., Pittsburgh, Pa. 
From 1975 to 7985, 60 patients with isolated hepatic metastases from colorectal cancer 
were treated by 77 right trisegmentectomies, five left trisegmentectomies, 20 right 
lobectomies, seven left lobectomies, eight left lateral segmentectomies, and three 
nonanatomic wedge resections. The 1-month operative mortality rate was 0%. One- to 
5-year actuarial survival rates of the 60 patients were 95%, 72%,53%,45%, and 45%, 
respectively. The survival rate after liver resection was the same when solitary lesions 
were compared with multiple lesions. However, none of the seven patients with four or 
more lesions survived 3 years. The interval after colorectal resection did not influence 
the survival rate after liver resection, and survival rates did not differ statistically when 
synchronous metastases were compared with metachronous tumors. A significant 
survival advantage of patients with Dukes' B primary lesions was noted when 
compared with Dukes' C and D lesions. The pattern of tumor recurrence after liver 
resection appeared to be systemic rather than hepatic. The patients who received 
systemic chemotherapy before clinical evidence of tumor recurrence after liver resection 
wrvived longer than those who did not. 
From the Department of Surgery, University of Pittsburgh Health Center, University of 
Pittsburgh, imd the Veterans Administration Medical Center, Pittsburgh, Pa. 
THE LNER IS a major site of metastatic spread of 
primary colorectal cancer, and it is the sole site of 
initial tumor recurrence in as many as 30% of patients. 
With further technical refinements in hepatic surgery 
and recent developments in sophisticated perioperative 
management, major liver resection can now be per-
formed with an operative mortality rate of less than 
5%.1-3 Thus surgical removal of hepatic metastases has 
been used with increasing frequency, particularly with 
colorectal carcinoma as the primary cancer. 
In this article, our experience in 60 patients who had 
liver resections for metastatic colorectal cancer will be 
analyzed to identify factors that may influence the 
outcome of surgery and also to study the patterns of 
tumor recurrence after potentially cllrative hepatic 
resection of metastatic tumor. 
PATIENTS AND METHODS 
During a 10-year period from 1975 to 1985, 60 
patients with isolated hepatic metastasis from colorec-
Presented at the Forty-third Annual Meeting of the Central 
Surgical Association, Chicago, IlL, March 6-8, 1986. 
Supponed by the National Institutes of Health research 
project grant No. AM-29961. 
Reprint requests: Shunzaburo Iwalsuki, M.D., Depart-
ment of Surgery, 3601 Fifth Ave., Rm. 218 Falk Clinic, 
Pittsburgh, PA 15213. 
804 SURCERY 
tal cancer were treated with various types of liver 
resection at the University Health Sciences Center of 
Colorado (16 patients before 1981) and the University 
Health Center of Pittsburgh (44 patients after 1981). 
There were 44 men and 16 women. The ages ranged 
from 25 to 76 years with a mean age of 55 years. The 
interval between colorectal resection and hepatic resec-
tion ranged from 0 (simultaneous resection) to 216 
months, with the median interval of 19 months. There 
were 16 patients with Dukes' B colorectal cancer, 31 
patients with Dukes' C, and 13 patients with Dukes' D 
lesions. The colorectal cancer with synchronous hepatic 
metastases was classified as Dukes' stage D, regardless 
of the stage of primary lesion. Thirty-eight patients 
had solitary hepatic lesion, and 22 patients had multi-
ple lesions. Among the 22 patients with multiple 
hepatic lesion!!, seven patieIlts' had four or more 
lesions. 
Liver resections for these 60 patients consisted of 17 
right trisegmentectomies,' five left trisegmentectomies,5 
20 right lobectomies, seven left lobectomies, eight left 
lateral segmentectomies, and three nonanatomic wedge 
resections. The extent and location of the tumor 
determined the choice of resection. After liver resection, 
systemic chemotherapy was recommended to all 
patients and their referring physicians and surgeons. 
Twenty-two patients followed the recommendations 
and received systemic chemotherapy before clinical 
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Fig. 1. Overall survival rate of 60 patients after liver 
resection for metastatic colorectal cancer. 
evidence of tumor recurrence and 28 patients did not. 
The most commonly used chemotherapeutic agent was 
5-fluorouracil for 6 to 18 months. 
Survival rates were calculated by the life table 
method of Kaplan-Meier, apd statistical comparisons 
among the subgroups were performed with the log-
rank test. 
RESULTS 
Operative mortality and morbidity. There were 
no deaths within a month after 22 trisegmentectomies, 
27 lobectomies, eight segmentectomies, and three 
wedge resections. Thus the 30-day operative mortality 
rate was 00/0. However, there were eight significant 
postoperative complications. Four patients developed 
subphrenic abscesses that required surgical drainage, 
two patients developed deep vein thrombosis, one of 
which caused a pulmonary embolus, and one patient 
developed small bowel obstruction. There were no 
postoperative hemorrhages that led to reexploration. 
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Survival. Overall actuarial survival rates calculated 
by the Kaplan-Meier method are shown in Fig. 1. 
One- to 5-year actuarial survival rates of the 60 
patients were 950/0, 720/0, 530/0, 450/0, and 450/0, respec-
tively. When the survival rates of 38 patients with 
solitary hepatic lesions were compared with those of 
:he 22 patients with multiple lesions, they were nearly 
, Identical as shown in Fig. 2. However, the survival rate 
r. of seven patients who had four or more hepatic lesions 
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Fig. 2. Survival rate after liver resect.ion for metastatic 
colorectal cancer by number of lesions. 
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Fig. 3. Survival rate after liver resection for metastatic 
colorectal cancer by Dukes' staging. 
was significantly less than that of 38 patients with a 
solitary lesion (p = 0.05) (Fig. 2). 
The influence of Dukes' staging of primary colorec-
tal cancer on survival after liver resection was exam-
ined (Fig. 3). The survival rate of 16 patients with 
Dukes' B primary lesions was significantly higher than 
that of the 31 patients with Dukes' C primary lesions 
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Fig. 4. Survival rate after liver resection for metastatic 
colorectal cancer by interval between colorectal and hepatic 
resection. 
or the 13 patients with Dukes' D lesions (p < 0.05). 
However, there was no difference in survival rates, 
after liver resection between patients with Dukes' C 
lesions and those with Dukes' D stage (synchronous 
hepatic lesion) colorectal cancers. 
The survival rates after liver resection were com-
pared by the interval after colorectal resection (Fig. 4). 
There was no difference in survival rates between 
patients with intervals less than 1 year, 1 to 2 years, 
and longer than 2 years. 
The survival rates were compared among 22 patients 
after trisegmentectomies, 27 patients after lobectomies, 
and 11 patients after left lateral segmentectomies or 
wedge resections (Fig. 5). The survival rate of patients 
whose hepatic metastases could be totally removed only 
by trisegmentectomies was significantly lower than that 
of patients whose hepatic lesions could be easily 
removed by lobectomies or smaller resections (p = 
0.01). The survival rates after lobectomies and left 
lateral segmentectomies or wedge resections were 
essentially identicaL 
The survival rate of 22 patients who received 
systemic chemotherapy before clinical evidence of 
tumor recurrence after hepatic resection was better 
than that of 38 patients not so treated (Fig. 6) 
(p = 0.05). 
Although the survival rate of patients who were 70 
years old or older was the lowest, there were no 
statistically significant differences among the different 
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Fig. 5. Survival rate after liver resection for metastatic 
colorectal cancer by extent of liver resection. 
age-groups (Fig. 7). There were no differences in 
survival rates between 44 men and 16 women. 
Tumor recurrence. Tumor recurrence was docu-
mented in 29 of the 60 patients from 3 months to 7 
years after liver resection, most frequently during the 
second year. The liver was involved in 18 patients, the 
abdomen outside the liver in 17 patients, the lungs in 
15 patients, the brain in five patients, the bones in four 
patients, and in one patient each, the abdominal wall, 
chest wall, and pericardium, respectively. It was diffi-· 
cult to determine the first site of recurrence in most of 
our patients by retrospective study. Most of the tumor 
recurrences involved multiple organs, and the liver was 
the isolated site of recurrence in only three patients. 
The lungs were the isolated site of recurrence in only 
two patients. 
DISCUSSION 
This study has confirmed earlier reports1.} that 
major hepatic resections can be performed with a 
minimum of risk to the patient. Petrelli et al." reported 
that right trisegmentectomy had been abandoned at 
Rosewell Park Memorial Institute for metastatic colo-
rectal cancer because of high surgical mortality rates. 
However, our experience of no operative deaths (death 
within 1 month) in 22 trisegmentectomies encourages 
the construed use of trisegmentectomy for extensive 
hepatic metastasis. 
The 1-, 3- and 5-year survival rates of 95%, 33%, 
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Fig. 6. Survival rate after liver resection for metastatic 
colorectal cancer with or without systemic chemotherapy 
before clinical evidence of tumor recurrence. 
and 45%, respectively, in this study reemphasize that 
liver resection is the therapeutic modality that offers 
the best prospect of long-term survival to a small but 
significant proportion of patients with metastatic 
hepatic lesions from colorectal cancer. Although it is 
difficult to compare the survival rates of different 
series, slightly better results of current series than those 
of others2, 3, 6-8 may reflect the lack of operative deaths 
and the liberal use of lobectomies and trisegmentectom-
ies in preference to the less radical nonanatomic 
resections often called "local excisions." 
Controversy has existed about the efficacy of major 
liver resection in controlling multiple hepatic metasta-
sis. It has been reported that multiple hepatic lesions 
have a poorer prognosis than do solitary lesions after 
liver resection.9,10 . However, in more recent 
studies,2,3, 6-8 statistically significant differences in sur-
vival rates could not be found after liver resections in 
patients with solitary versus multiple hepatic lesions, 
The present study supports the latter conclusion, but it 
is noteworthy that none of the seven patients with four 
or more hepatic lesions in this series survived 3 years 
after liver resection. 
The stage of primary colorectal cancer appeared to 
be a determinant of survival after resection of hepatic 
metastases. A significant survival advantage was seen 
for patients with Dukes' B primary lesions when 
compared with patients with Dukes' C. Others have 
reported the same finding.2, 3, 7, 8 The survival rate of 
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Fig. 7. Survival rate after liver resection for metastatic 
colorectal cancer by age. 
patients with synchronous hepatic metastasis (Dukes' 
D) did not differ from that of patients with metachro-
nous tumors of Dukes' C primary lesions, but it was 
significantly less than that of patients with metachro-
nous tumors Dukes' B lesions. Because only two of the 
13 patients with synchronous tumors had primary 
colorectal cancer of Dukes' B stage, the real influence 
of synchronous hepatic metastasis on survival after 
liver resection could not be determined. However, the 
findings of this series and those of others2, 3, 7, 8 indicate 
that the interval between colorectal and hepatic resec-
tion is not a factor that affects survival after liver 
resection. Therefore, synchronous hepatic metastases 
appear to be treated by liver resection as effectively as 
metachronous metastases. 
The extent of liver resection was determined by the 
degree of tumor involvement of the liver. Trisegmen-
tectomies were applied to the tumors that involved both 
lobes. Inferior survival after trisegmentectomies merely 
reflected more advanced stage of metastatic colorectal 
cancer when compared with lobectomies or smaller 
resections. 
The effect of systemic chemotherapy before clinical 
evidence of tumor recurrence after liver resection was 
not examined by a randomized study, but the survival 
rate of patients who received chemotherapy before 
tumor recurrence was significantly better than that of 
those who did not (p = 0.05). Well-designed multi-
institutional studies involving a large number of 
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patients will be required to confirm our finding. 
The pattern of tumor recurrence or treatment failure 
after liver resection appeared to be systemic rather than 
hepatic in this experience and that of others,6, 11 realiz-
ing that any retrospective study to determine the first 
sites of recurrence by clinical tests has limitations. 
However, even the limited information now available 
suggests that systemic chemotherapy may be at least as 
effective in controlling tumor recurrences after liver 
resection as intrahepatic infusion chemotherapy. 
The following multi-institutional study should be 
considered to determine the effect of systemic adjuvant 
chemotherapy on survival after potentially curative 
liver resection of metastases from colorectal cancer. 
Patients with an elevated carcinoembryogenetic anti-
gen before liver resection, which falls to normal levels 1 
month after liver resection, would be randomized into 
either one group receiving systemic chemotherapy or 
another without this adjuvant therapy. Carcinoem-
bryogenetic antigen levels would be measured every 3 
months as an indicator of treatment failure. If the 
treatment were to fail, the sites of recurrence would be 
investigated extensively every 3 months to determine 
the pattern of treatment failure. Tumor-free intervals 
and survival rates would be compared between the two 
groups. Our group would be compelled to refrain from 
participation in such a study, since the statistically 
significant better results in our patients given chemo-
therapy would not allow us to have a null hypothesis of 
no treatment difference. 
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DISCUSSION 
Dr. Jeremiah G. Turcotte (Ann Arbor, Mich.). Dr. 
Iwatsuki did not mention it in his presentation, but with their 
operative mortality rate of 0% for 60 major liver resections it 
will be some time before another group will duplicate this 
outstanding result. 
The 45% survival rate 'at 5 years certainly makes one 
wonder if we are not somehow altering the biology of this 
tumor with this major intervention. To have such a high 
proportion of patients alive 5 years after the tumor has 
metastasized to the liver seems very unusual. Of course, we 
will never answer the question of whether this is just selection 
unless a prospective randomized study is accomplished. 
However, the results from this and other series certainly 
suggest that resection of metastatic colon cancers is a worth-
while undertaking. 
I thought it would be useful to compare the results of this 
series with the results reported by Flanigan and Foster in 
1967. Their communication in 1967 brought the subject to 
the attention of the surgical world. Their series was a 
collected series rather than a personal series. 
In 1967 operative mortality rates varied from 4% to 30%. 
The operative mortality rate for most groups was closer to 
30%. In Dr. Iwatsuki report the 30-day operative mortality 
rate was 0%. The 5-year survival rate reported by Flanigan 
was 24%, while in the present report it is 45%. Much of the 
improvement in survival is due to a lower operative mortality 
rate. 
Both Iwatsuki's and Foster's report noted a decrease in 
survival with multiple lesions. With four or more lesions no 
patient survived 5 years in Iwatsuki's experience. In Foster's 
report the 5-year survival rate was 12% with multiple lesions, 
but the term "multiple" was not defined. When more 
extensive resections, that is, trisegmentectomy, was required, 
the long-term survival rate was approximately 13% in the 
Pittsburgh report and 20% in the Flanigan report. 
I have three questions. Do you continue to recommend an 
operation when a trisegmentectomy is required to remove the 
tumor, since you have experienced only a 13% 3-year survival 
rate with this operation? Likewise, do you continue to 
recommend resection with four or more lesions, since there 
were no long-term survivors in this group? Would you also 
comment on the use of hepatic resection for other types of 
tumors, especially sarcomas, since there is evidence th2t 
suggests this may be worthwhile. 
Dr. Joaquin S. Aldrete (Birmingham, Ala.), It is obviouS 
from the article by Dr. Iwatsuki et al. and the one presented 
by Dr. Gordon, both from the Pittsburgh group, that they 
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perform liver resections as do most of us in minor cases in 
between or while waiting for the major cases. In Pittsburgh 
the major cases are, of course, liver transplants. I personally 
have witnessed this impressive routine that Tom Starzl and 
his group have had for a number of years. 
I think this is an important article, particularly the 
conclusions that the actuarial survi val curves of these patients 
are improved. Another meaningful conclusion was that the 
localized lesions that can be resected with a simple right or 
left lobectomy have better survival rates than those that 
require an extensive resection or those with multiple metas-
tases. These observations were also made by the multicenter 
study that included more than 600 patients and that was done 
by the surgeons at the National Cancer Institute, presented a 
few weeks ago at the Society of University Surgeons. 
I also think that in the study presented, there may be an 
element of selection that allowed the observed good results. I 
noticed, Dr. Iwatsuki, that your mean period of time elapsed 
between the resection of the primary colonic tumor and the 
resection of the hepatic metastases was 19 months. This can 
be interpreted as a valid way of natural selection since 
patients who can be well after their primary colon resection 
without having signs of obvious hepatic metastases appear to 
have a much better prognosis. We have noticed this in our 
own experience; perhaps there is some wisdom in waiting 2 
or 3 months after the hepatic metastasis has been detected, 
then repeat the computerized tomography, and when there 
has been little change in the size and number of the 
metastases, the probabilities for longer survival are better 
after resection of the slow-growing metastases. This is what I 
mean when I talk about "natural selection." Therefore my 
question is: did you analyze the survival curves specifically in 
relation to the duration between the resection of the primary 
colonic cancer and the resection of the hepatic metastases? 
Dr. Larry C. Carey (Columbus, Ohio). I think the group 
from Minnesota, at this meeting 3 or 4 years ago, presented a 
review of their initial group of patients on whom Dr. 
WangensH:en had recommended second looks. For my infor-
mation it provided the first evidence that multiple hepatic 
metastases were not quite as ominous as we had thought. Dr. 
Delaney, do you or any of the other Minnesota representa-
tives want to comment about your updated experience with 
those patients!' 
Dr. Delaney. I have no later update. 
Dr. Carey. We have had a fairly similar experience in a 
series of about 50 cases now at Ohio State, also without a 
death, with a 5-year survival rate of about 35%. I think as 
more and more centers present these problems, the data 
Liver resection for metastatic colorectal cancer 809 
appear to become more and more similar in long-term 
outcome. 
Dr. Iwatsuki (closing). Answering the question about 
trisegmentectomies for metastatic colorectal cancer, we will 
continue to treat those bilobar tumors by extensive liver 
resections. The 4-year survival rate is low. However, 1- and 
2-year survival rates are excellent. There is no statistical 
difference in survival rates at the 1- and 2-year level between 
trisegmentectomies and lobectomies. This means that these 
tumor-free periods give us an opportunity to treat these 
patients with adjuvant chemotherapy. Adjuvant chemothera-
py after curative resection of colorectal metastastases is not 
well accepted by oncologists or oncologic surgeons, but our 
data strongly suggest that chemotherapy does something 
positive after curative resection. Therefore we will continue 
to perform trisegmentectomies for metastatic tumor if the 
liver is the only site of metastasis. 
There was a question about liver resection for other 
metastatic liver tumors. We have done approximately 300 
liver resections since Dr. Starzl started to collect data on 
patients with liver resection. There were roughly 100 
patients with benign disease, 100 patients with metastatic 
tumors, and 100 cases of primary liver cancer. 
The second most common metastatic tumor was carcinoid 
tumors, followed by leiomyosarcoma, a few cases of breast 
cancer, and ovary tumors and melanomas. We have not 
analyzed these small numbers of cases in detail yet, but I 
believe liver resections provided significant tumor-free time 
for those patients. 
Both Drs. Turcotte and Aldrete asked about case selection 
of our patients with liver resection. We do not have any 
choice in selecting our patients. Most of the patients came to 
us, as you can see from the extent of the liver resections, after 
rejection by other institutions. Thus we are not picking up 
small tumors of a smaller number of metastases. Rather we 
are treating more advanced metastatic colorectal cancer than 
do other institutions. 
We do not perform the resections if there is obvious distant 
extrahepatic involvement of the tumors. Many centers do 
resections with obvious periaortic node involvement but we 
do not. However, we perform resection on the patient with 
extrahepatic involvement by extension, such as to the dia-
phragm or adrenals or kidneys. 
We have analyzed and presented that time interval 
between the colon and liver resection does not influence the 
survival rates after liver resection. This is also true for 
synchronous tumors. 
Reseccion hepatica en casos de carcinoma colorrectal metastasico 
Desde 1975 hasta 7985 se trataron 60 pacientes con metastasis hepaticas aisladas con 
primario en un carcinoma colorrectal. Se realizaron 17 trisegmentectomias derechas, 5 
izquierdas, 20 lobectomias derechas, 7 izquierdas, 8 segmentectomias laterates 
--------~-- .. -----
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izquierdas y 3 reseccianes no anatomicas en cuiia. La mortalidad operataria en el 
primer mes fue de 0%. La supervivencia actuaria de los 60 pacientes jue de 95, 72, 53, 
45, Y 45% respectivamente. La supervivencia despues de la reseccion hepatica fue 
similar en Los casos can lesiones salitarias que en los casas con lesiones muLtipLes. Sin 
embargo ninguno de los 7 pacientes con cuatro 0 mas lesiones sobrevivio mas de 3 
aiios. EL penodo de tiempo despues de la resecciim colarrectal no inJfuyo en La 
supervivencia despues de realizar La reseccion hepatica, y la supervivencia no mostro 
diferencias estadisticas importantes wando se compararon las metastasis sincronicas 
con los tumores metacronos. Se observo una importante ventaja de supervivencia de los 
pacientes con lesiones primarias tipo Dukes B wando se compararon con las lesiones 
Dukes C y Dukes D. EL patron de recurrencia tumoral despues de fa reseccion 
hepatica parece ser sistemico mas que hepatico. Los pacienles que recibieron 
quimioterapia sistemica antes de que hubiese evidencia clinica de rewrrencia del tumor 
despues de haber realizado La reseccion hepatica, tuvieron una supervivencia mayor 
que aquellos que no recibieron quimioterapia. 
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